News

Some histamine-2 receptor blocker medications like Zantac were initially ruled out as safe by the FDA. It was a drug for patients who experience heartburn and other gastrointestinal illnesses. Individuals with gastroesophageal reflux disease (GERD) and excessive stomach acid...

Codivir, a short synthetic 16 amino-acid peptide, derived from the HIV-1 integrase, was originally discovered at the Hebrew University in Israel. Code Pharma discovered that the peptide had a direct antiviral effect against SARS-CoV-2, the novel Coronavirus causing COVID-19. In-vitro...

NRx Pharmaceuticals has reported additional data from Phase IIb/III clinical trial where its drug, Zyesami (aviptadil), offered a rise in blood oxygen within a day in critical Covid-19 patients with acute respiratory failure. Zyesami is a synthetic form of vasoactive...

Virpax Pharmaceuticals, a company specializing in developing product candidates for pain management, CNS and anti-viral indications, has entered into a commercial manufacturing and supply agreement with Seqens, an integrated global leader in pharmaceutical solutions with 24 manufacturing sites worldwide...

Quotient Sciences, a drug development and manufacturing company, is investing £6.3 million pounds ($8.6mn) in its recently acquired manufacturing facility in Alnwick, UK. The investment will expand Quotient’s drug substance manufacturing capability and will create 80 new jobs over...

Innovent Biologics, Inc., a biopharmaceutical company that develops, manufactures and commercializes medicines for cancer, metabolic, autoimmune and other diseases, and Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents, entered a collaboration to research...

SK bioscience (SK) and GlaxoSmithKline (GSK) announced the initiation of a phase 3 clinical study of SK’s Covid-19 vaccine candidate, GBP510, in combination with GSK’s pandemic adjuvant following positive interim phase 1/2 results. The randomised, active-controlled global trial will enroll...